SCHEMBL3059243

SCHEMBL3059243

COc1ccc(CN2CCc3cc(OCc4ccccc4)c(OC)cc3C2)cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.78
CHRNA7 P36544 2/20 0.67
MAPK1 P28482 2/20 0.66
HSD17B10 Q99714 1/20 0.66
KDM4E B2RXH2 4/20 0.64
TDP1 Q9NUW8 1/20 0.64
RAB9A P51151 2/20 0.63
NPC1 O15118 1/20 0.63
ABCB1 P08183 5/20 0.60
ABCC1 P33527 3/20 0.60
KMT2A Q03164 2/20 0.60
ABCG2 Q9UNQ0 2/20 0.60
MEN1 O00255 1/20 0.58
MAPT P10636 2/20 0.58
GAA P10253 1/20 0.58
ALDH1A1 P00352 2/20 0.58
HTT P42858 2/20 0.58
LMNA P02545 1/20 0.58
TSHR P16473 1/20 0.58
NPSR1 Q6W5P4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050371 0.93 REV1 (0.84) REV1CHRNA7HSD17B10KDM4ETDP1
SCHEMBL3062442 0.90 REV1 (0.72) REV1CHRNA7KDM4ETDP1RAB9A
SCHEMBL3059193 0.90 REV1 (0.87) REV1CHRNA7KDM4ETDP1ABCB1
SCHEMBL3046416 0.89 REV1 (0.71) REV1CHRNA7KDM4ETDP1RAB9A
SCHEMBL3059849 0.89 REV1 (0.74) REV1CHRNA7KDM4ETDP1ABCB1
SCHEMBL3056974 0.89 REV1 (0.71) REV1CHRNA7MAPK1HSD17B10KDM4E
SCHEMBL3051227 0.88 REV1 (0.70) REV1CHRNA7MAPK1HSD17B10KDM4E
SCHEMBL3049335 0.88 REV1 (0.70) REV1CHRNA7KDM4ETDP1RAB9A
SCHEMBL3052241 0.88 REV1 (0.76) REV1CHRNA7KDM4ETDP1RAB9A
SCHEMBL3055739 0.87 REV1 (0.72) REV1CHRNA7KDM4ETDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
EP-2211856-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS The Hospital For Sick Children (CA) 2010-08-04 EP claimed
WO-2009073564-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS THE HOSPITAL FOR SICK CHILDREN (CA) 2009-06-11 WO claimed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC REV1 1520/4885CHRNA7 4760/4885MAPK1 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.